Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.

A study led by Dr. Manel Mendoza from Vall d’Hebron shows that studying the levels of placental markers is as effective as Doppler ultrasounds, the standard method for classifying the risk of pregnancies with low birth weight fetuses.

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.

The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.

You can now register for the Master's Degree in Translational Biomedical Research, the Master's Degree in Clinical Trial Management and Coordination and, as a novelty, the Master's Degree in Health Innovation and Entrepreneurship.

The EXPOSIM project will investigate the impact of environmental stressors such as pollution, noise and aeroallergens on immune-mediated diseases.

In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.

The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.

The Association for the Information and Research of Familial Hypomagnesemia, once again, has shown its solidarity with a donation of €19,000.

VHIR collaborates in the development of nanoGLA, an innovative nanotechnology therapy to treat Fabry disease. It has demonstrated high efficacy in preclinical studies, highlighting its effectiveness in addressing neurological manifestations.

A key initiative that connects researchers with a network of more than 20 external mentors who are experts in various fields within the ecosystem.

Members of the RBDCOV project, which involves VHIR, gathered at the Palau Macaya to review progress and achievements made during the final phase of the project.

The grants, totalling almost three million euros, promote the training of the next generation of research professionals and support the development of new technologies.

Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.

Hypertension, a key risk factor for heart disease that contributes significantly to cardiovascular mortality and morbidity and damage to vital organs, was the focus of this multi-centre study.

This project is promoted by the Pasqual Maragall Foundation with the support of Barcelona City Council. It involves some of the city's main public hospitals and institutions specialising in research into Alzheimer's disease.

The Parc Taulí and Vall d’Hebron spin-off has raised €2.77 million in private and public funds, enabling it to complete the necessary clinical trials to obtain CE marking and bring this device to market.

Vall d'Hebron researchers have created a score based on multiple clinical variables and cardiac images, specific to women, to identify patients at risk of severe complications such as a heart attack or sudden death.

The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.

INDICATE will lay the foundations for the training and operation of an AI model implemented in intensive care units to support personalised medicine applications, data comparison between ICUs and preparedness for possible disasters.

The sessions were aimed at establishing new collaborations to advance the prevention and treatment of this type of tumour.